Stockreport

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 [Yahoo! Finance]

Candel Therapeutics, Inc.  (CADL) 
PDF company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation [Read more]